Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with ...

ROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise ...

Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immunosuppression drugs ZURICH, July 17, ...

BullFrog AI Holdings, Inc. has published a letter from CEO Vin Singh to stockholders, highlighting significant progress in 2024 and outlining future plans for 2025. The company has advanced its ...